A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV) gemcitabine in participants with locally advanced or metastatic pancreatic cancer. The anticipated time on study treatment is 3 to 12 months, and the target sample size is 56 individuals.
Pancreatic Cancer
DRUG: Capecitabine|DRUG: Gemcitabine
Overall objective response rate, At the end of 6 cycles (24 weeks)
Duration of response, Up to approximately 3.5 years|Time to disease progression, Up to approximately 3.5 years|Time to response, Up to approximately 3.5 years|Time to treatment failure, Up to approximately 3.5 years|Overall survival, Up to approximately 3.5 years|Incidence of adverse events, Up to approximately 3.5 years
This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV) gemcitabine in participants with locally advanced or metastatic pancreatic cancer. The anticipated time on study treatment is 3 to 12 months, and the target sample size is 56 individuals.